Sun, Nov 23, 2014, 1:10 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

pharmatheway 77 posts  |  Last Activity: Nov 20, 2014 10:37 AM Member since: May 4, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Dr.Sharman used a graph to explain the difference between Ibrutinib by itself and when used in conjunction with Ublituximab. It looks like the Ublituximab assists the Ibrutinib in killing cll cells and causes faster reactions with fewer side effects. One reason why this will be granted FDA approval.IMO .That statement was made at the end of september 2014.

    Sentiment: Strong Buy

  • Reply to

    JNJ on the hunt -GERN 935M Deal!

    by golderw3 Nov 13, 2014 7:30 PM
    pharmatheway pharmatheway Nov 18, 2014 3:06 PM Flag

    Janssen Biotech, Inc., Pharmacyclis, Inc., and TG Therapeutics, Inc.

    Looking Toward Future Management of B-Cell Lymphomas

    Leo I. Gordon, MD, Northwestern University Feinberg School of Medicine, Chicago, IL: indicated no conflicts of interest.
    Michael J. Keating, MD, The University of Texas MD Anderson Cancer Center, Houston, TX: consultant for Celgene Corporation and Roche; advisory board for GlaxoSmithKline.
    David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA: honoraria from Dr. Reddy’s Laboratories, Ltd., Genentech, Pharmacyclics, Inc., Roche, and Seattle Genetics.
    John Sweetenham, MD, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT: speaker for Seattle Genetics.

  • Reply to

    JNJ on the hunt -GERN 935M Deal!

    by golderw3 Nov 13, 2014 7:30 PM
    pharmatheway pharmatheway Nov 18, 2014 3:03 PM Flag

    At ASH 2014.Looking Tow#$%$rd Future M#$%$n#$%$gement of B-Cell Lymphom#$%$s

    Register now
    This progr#$%$m is jointly sponsored by the University of Cincinn#$%$ti #$%$nd Educ#$%$tion#$%$l Concepts Group, LLC, #$%$nd supported by J#$%$nssen Biotech, Inc., Ph#$%$rm#$%$cyclics, Inc., #$%$nd TG Ther#$%$peutics, Inc.

    Loc#$%$tion: S#$%$n Fr#$%$ncisco M#$%$rriott M#$%$rquis
    Rooms: Golden G#$%$te B#$%$llroom, S#$%$lon B

    Spe#$%$kers: Leo I. Gordon, MD, FACP Northwestern University Feinberg School of Medicine, Chic#$%$go, IL
    D#$%$vid M#$%$loney, MD, PhD, Fred Hutchinson C#$%$ncer Rese#$%$rch Center, Se#$%$ttle, WA
    Mich#$%$el Ke#$%$ting, MD, The University of Tex#$%$s MD Anderson C#$%$ncer Center, Houston, TX
    John Sweetenh#$%$m, MD, FRCP Huntsm#$%$n C#$%$ncer Institute, University of Ut#$%$h, S#$%$lt L#$%$ke City, UT
    Mich#$%$el Willi#$%$ms, MD, University of Virgini#$%$ He#$%$lth System, Ch#$%$rlottesville, VA

    This inter#$%$ctive, educ#$%$tion#$%$l progr#$%$m will provide #$%$ hem#$%$tology-oncology review of recently published #$%$nd emerging d#$%$t#$%$ in follicul#$%$r lymphom#$%$, m#$%$ntle cell lymphom#$%$, l#$%$rge B-cell lymphom#$%$, #$%$nd chronic lymphocytic leukemi#$%$. Led by #$%$ group of f#$%$culty le#$%$ders, e#$%$ch with more th#$%$n 30 ye#$%$rs of p#$%$tient c#$%$re experience, the session will combine both rese#$%$rch evidence #$%$nd clinic#$%$l experience to help #$%$ttendees determine how to best #$%$pply existing d#$%$t#$%$ to clinic#$%$l pr#$%$ctice tod#$%$y to improve dise#$%$se m#$%$n#$%$gement #$%$nd p#$%$tient outcomes.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 18, 2014 9:48 AM Flag

    How about time for you to cover and mover on.Dec. will be big ASH DEc. 6-9, 2014 TGTXl Efficacy and safety will be updated on all enrolled patients.at ASH.Don't bet against them.IMO

    Sentiment: Strong Buy

  • https://ash.confex.com/ash/2014/webprogram/Paper73029.html Conclusions: Data suggests ublituximab, a glycoengineered anti-CD20 mAb, in combination with ibrutinib is both well-tolerated and highly active in patients with relapsed or refractory CLL and MCL. ORR was 94% in patients with CLL (100% in patients with high risk CLL: 17p, 11q del with 1 CR), with responses attained rapidly (median TTR: 8 weeks). In MCL, 83% of patients achieved a response at first efficacy assessment, with 50% of patients achieving a CR by week 20. For most patients, responses improved by the second efficacy assessment. The addition of ublituximab appears to mitigate ibrutinib related lymphocytosis producing earlier clinical responses than historically seen with ibrutinib monotherapy. Efficacy and safety will be updated on all enrolled patients.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 12, 2014 12:09 PM Flag

    bump

    Sentiment: Strong Buy

  • Reply to

    Nice close.

    by pharmatheway Nov 11, 2014 4:02 PM
    pharmatheway pharmatheway Nov 11, 2014 6:58 PM Flag

    In Oct .you wished for it to be over 10.00 per share well it is.No joke i was in PCYC when it was $3.00 now look at it .Patience is a virtue.Everything takes time.

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Nov 11, 2014 4:02 PM Flag

    10,374 shares buy @12.91 at the bell.

    Sentiment: Strong Buy

  • www.streetinsider.com/Analyst+Comments/Roth+Positive+on+TG+Therapeutics+%28TGTX%29+Following+Q3+Results%3B+Expects+Strong+ASH+Showing/9999622.html?si_client=st

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Nov 10, 2014 10:23 AM Flag

    www.cllforum.com/forum63/12341-2.html Go and see how good this trial is going for folks.A snippet :Had a CT scan and it looks like all the pieces are where they belong. The spleen, liver and nodes are no longer swollen and numbers are reasonable. Don't see that I have any side effects from the Ublituxamab and I also did not have the wild number swings that a lot of you have for the first months of taking Ibrutinib. I don't feel like I am twenty years old but I feel reasonably healthy and could enjoy the rest of my life if I stayed like this.

    Three more cycles in this trial and my humble opinion is that it is more than successful.

    Sentiment: Strong Buy

  • Reply to

    ACHN Announcement at AASLD...

    by vol_96 Nov 9, 2014 8:26 AM
    pharmatheway pharmatheway Nov 9, 2014 12:42 PM Flag

    Yep way off.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 7, 2014 10:11 AM Flag

    To hell with the world we leave our children.With Republicans now in control of the Senate, we're likely to see a bill to push through the Keystone XL pipeline coming down the pike soon. And Mitch McConnell, probably the coal industry's biggest booster, retained his seat.

    In fact, McConnell and his climate-denying colleague James Inhofe of Oklahoma—the likely chair of the Senate's Environment and Public Works committee—won a lot of new friends on Capitol Hill last night. It probably won't surprise you to learn that most of the Senate's newly elected Republicans are big boosters of fossil fuels and don't agree with the mainstream scientific consensus on global warming. Here's an overview of their statements on climate change, ranging from a few who seem to at least partly accept to science to those who flat-out reject it.

    Dan Sullivan (R-Alaska): In September, Sullivan, a former Alaska attorney general, said "the jury's out" on whether climate change is man-made. (Actually, the jury came in, for the umpteenth time, just this week.) He repeated that position last month, when he said the role human-caused greenhouse gases play in global warming is "a question scientists are still debating," adding that "we shouldn't lock up America's resources and kill tens of thousands of good jobs by continuing to pursue the President's anti-energy policies."

    Tom Cotton (R-Ark.): Cotton has seized on a common but misleading notion among climate change deniers: "The simple fact is that for the last 16 years the earth's temperature has not warmed." He admits, however, that "it's most likely that human activity has contributed to some of" the temperature increase of the last hundred years. Still, he supports building new coal plants and the Keystone XL pipeline.

    Cory Gardner (R-Colo.): Gardner is shifty on the issue. In a debate last month, he wouldn't give a straight yes-or-no answer on whether mankind has contributed to global warming. "I believe that the climate is changing, I disagree to the extent that it's been in the news," that humans are responsible, he said. Yet at the same time, he admitted that "pollution contributes" to climate change. Gardner doesn't seem interested in cleaning up that pollution: Last year he said the Obama administration is waging "a war on the kind of energy we use every day—fossil fuels… because they want to tell us how we live our lives."

    David Perdue (R-Ga.): "In science, there's an active debate going on" about whether climate change is real, Perdue told Slate this year, adding that if there are climate-related impacts to Georgia's coast, some smart person will figure out how to deal with them. Perdue has also slammed the Obama administration for waging a "war on coal" and has called the EPA's new carbon emission rules "shortsighted."

    Joni Ernst (R-Iowa): Ernst is another rider on the "I don't know" bandwagon. "I don't know the science behind climate change," she told an audience in September. She also hedged the question beautifully in a May interview with The Hill: "I haven't seen proven proof that it is entirely man-made." But she supports recycling!

    Bill Cassidy/Mary Landrieu (La.): This race is going to a runoff. Landrieu, the incumbent Democrat, has never been much of a climate hawk—she recently said humans do contribute to observed climate change but criticized Obama for "singling out" the oil industry for regulation. But at least she's better on global warming than Cassidy, her Republican challenger, who flatly denies that climate change exists. He said last month that "global temperatures have not risen in 15 years."

    Steve Daines (R-Mont.): Daines is a harsh critic of Obama's energy and climate policies, which he said "threaten nearly 5,000 Montana jobs and would cause Montana's electricity prices to skyrocket." While in the House, he signed a pledge that he will "oppose any legislation relating to climate change that includes a net increase in government revenue." He believes global warming, to the extent that it exists, is probably caused by solar cycles.

    Thom Tillis (R-N.C.): During a North Carolina Republican primary debate, all four candidates laughed out loud when asked if they believed climate change is a "fact." Ha! Ha! Then they all said, "No." Later, Tillis expanded on that position, arguing in a debate with his Democratic rival, Sen. Kay Hagan, that "the point is the liberal agenda, the Obama agenda, the Kay Hagan agenda, is trying to use [climate change] as a Trojan horse for their energy policy."

    Ben Sasse (R-Neb.): Sasse hasn't said much about climate science, but he supports building the Keystone XL pipeline and opening up more federal land for oil and gas drilling. He also wants to "encourage the production of coal."

    James Lankford (R-Okla.): As a member of the House, Lankford called global warming a "myth." He also, along with Gardner, Cotton, Shelley Moore Capito (R. W.Va.), Cassidy, and Daines, voted to prevent the Pentagon from considering the national security impacts of global warming, even though top Defense Department officials have repeatedly issued warnings that climate change could worsen conflicts around the world. Lankford also floated an amendment to an energy appropriations bill that would have blocked funding for research related to the social costs of carbon pollution.

    Mike Rounds (R-S.C.): Rounds appears to accept at least some of the science on climate change. As governor of South Dakota, Rounds said that "there are a number of different causes that we recognize, and the scientists recognize, are the cause of global warming," and that humans are "absolutely" one of those. He fervently supports the Keystone pipeline.

    Shelley Moore Capito (R-W.Va.): In a debate last month, Capito said, "I don't necessarily think the climate's changing, no." Then she clarified that her opinion might change with the weather: "Yes it's changing, it changes all the time, we heard it raining out there," she said. "I'm sure humans are contributing to it." I have no idea what that is supposed to mean. Capito is also a founding member of the Congressional Coal Caucus.

  • Roth Capital reiterates its Buy/Focus Pick rating and $25 price target on TG Therapeutics (Nasdaq: TGTX) after the company announced publication of its ASH 2014 abstracts, which include the combination studies of TG-1101 and TGR-1202, TG-1101 and Imbruvica and TG-1202 monotherapy.

    Analyst Joseph Pantginix commented, The data from all three studies show a good safety profile as well as positive efficacy outcomes across B cell malignancies ... We continue to be impressed with the positive data coming out from TGTX’s studies. We believe the data from the TGR-1202 monotherapy continues to show the differentiation of this PI3K inhibitor from others but we believe this study’s main importance is to characterize and support the ongoing combination study with TG-1101. The combination study of TG-1101 and TGR-1202 continues to show the favorable combinable aspects of these two candidate drugs and in particular their good safety profile that separates them from other anti-CD20 and PI3K inhibitors in the field. We are most impressed by the continued high ORR coming out from the TG-1101 and Imbruvica combination study. With the plethora of other combination studies ongoing and planned for Imbruvica (including with Gazyva), we believe these data (94% ORR to date in CLL) emphasize the favorability of this particular combination.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 7, 2014 9:23 AM Flag

    Gilead Sciences (NASDAQ: GILD) week 3 Harvoni TRx was 1984, up 79% week-over-week, according to RBC analyst Michael J. Yee, citing IMS. NRx was 1973, up 80%. Harvoni plus Sovaldi TRx was 6286 and NRx was 3326, up 20% and 42%, respectively.

    "So far, Harvoni launch is outpacing Sovaldi launch

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 6, 2014 6:44 PM Flag

    Do you know how to read? Key data from the Company's proprietary combination of TG-1101 and TGR-1202 trial in patients with chronic lymphocytic leukemia (CLL), and non-Hodgkin's lymphoma (NHL) will be presented in an oral presentation. In addition, poster presentations will include updates from the ongoing combination trial of TG-1101 plus ibrutinib, as well as from the ongoing single agent trial of TGR-1202. Do you know who Jeff P. Sharman, MD is?If not do some DD he will be a Presenter for Abstract Number: 4679 .

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Nov 6, 2014 5:36 PM Flag

    Brean Capital Reaffirms Buy On TG Therapeutics Following Publication Of ASH Abstracts n a research report published today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, as updated data from the company’s TG-1101 plus ibrutinib trial, the TG-1101 plus TGR-1202 trial, as well as the TG-1202 single agent trial became available.

    Aschoff observed, “The addition of TG-1101 generates earlier clinical responses than historically seen with ibrutinib monotherapy. The ORR was 94% in all CLL patients and was 100% in high risk CLL patients having both 17p and 11q del, with responses attained rapidly (median time was 8 weeks to response). Among the 8 high risk CLL patients, there were 1 CR and 7 PRs. The ORR was 83% in MCL patients, which was achieved at first efficacy assessment (prior to cycle 3), and further improved by the second efficacy assessment (prior to cycle 6). TG-1101 appears to control ibrutinib related lymphocytosis with more than half of the patients within the normal range for ALC by first efficacy assessment. As of August, 21 patients were enrolled with efficacy data in 15 (5 CLL and 10 NHL) and safety data in all 21 (8 CLL and 13 NHL) available. We expect TG to present data in at least 30 CLL and NHL patients on this regimen at ASH. ORR in CLL and NHL remained the same as what was presented in July. Four of the 5 CLL/SLL patients and 2 of the 10 NHL patients achieved a PR, and 80% of all 15 had reduced tumor burden at first assessment. No new DLTs and no events of TGR-1202 related hepatotoxicity were reported.”

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Nov 6, 2014 11:25 AM Flag

    Hematology Annual Meeting

    Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation

    Updates on the Combination of TG-1101 Plus Ibrutinib, and Single-Agent TGR-1202 to be Featured in Poster Presentations

    TG Therapeutics to Host a Reception on Monday December 8(th) from 7:45 pm -- 9:00 pm with Presentations by Leading Clinical Investigators

    NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that updated data for TG-1101 (ublituximab), the Company's novel, glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's PI3K delta inhibitor, has been selected for presentation at the upcoming 56(th) American Society of Hematology Annual Meeting (ASH), to be held December 6 -9, 2014, at the Moscone Center, in San Francisco, CA. Key data from the Company's proprietary combination of TG-1101 and TGR-1202 trial in patients with chronic lymphocytic leukemia (CLL), and non-Hodgkin's lymphoma (NHL) will be presented in an oral presentation. In addition, poster presentations will include updates from the ongoing combination trial of TG-1101 plus ibrutinib, as well as from the ongoing single agent trial of TGR-1202.

    Presentations on TG-1101 and TGR-1202 at the ASH meeting include the following:

    Oral Presentation:

    -- Title: Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody

    (mAb), In Combination With TGR-1202, A Next Generation Once Daily PI3k

    delta Inhibitor, Demonstrates Activity In Heavily Pre-Treated And

    High-Risk CLL And B-Cell Lymphoma

    -- Oral Session: 801

    -- Session: 624. Lymphoma: Therapy with Biologic Agents, excluding

    Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL

    -- Date and Time: Tuesday, December 9, 2014 at 8:00am, during 7:30 --

    9:00 AM Session

    -- Location: West Building, 2005-2007-2018-202

    -- Presenter: Matthew Lunning, DO

    Clinical Posters:

    -- Title: TGR-1202, A Novel Once Daily PI3K delta Inhibitor, Demonstrates

    Clinical Activity With A Favorable Safety Profile, Lacking Hepatotoxicity,

    In Patients With CLL And B-Cell Lymphoma

    -- Abstract Number: 1984

    -- Session: 642. CLL: Therapy, excluding Transplantation: Poster I

    -- Date and Time: Saturday, December 6, 2014: 5:30 PM- 7:30 PM

    -- Location: West Building, Level 1

    -- Presenter: Howard A. Burris III, MD

    -- Title: Ublituximab (TG-1101), A Novel Glycoengineered Anti-CD20

    Monoclonal Antibody, In Combination With Ibrutinib Is Highly Active In

    Patients With Relapsed and/or Refractory CLL And MCL; Results Of A Phase

    II Trial

    -- Abstract Number: 4679

    -- Session: 642. CLL: Therapy, excluding Transplantation: Poster III

    -- Date and Time: Monday, December 8, 2014: 6:00 PM- 8:00 PM

    -- Location: West Building, Level 1

    -- Presenter: Jeff P. Sharman, MD

    Pre-Clinical Posters:

    -- Title: Complementary Targeting of PI3K and the Proteasome Causes Potent

    Inhibition of mTORC1 and NF-KappaB in Models of B- and T-Cell Lymphoma

    -- Abstract Number: 1770

    -- Session: 625. Lymphoma: Pre-Clinical -- Chemotherapy and Biologic

    Agents: Poster I

    -- Date and Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM

    -- Location: West Building, Level 1

    -- Presenter: Changchun Deng, MD, PhD

    -- Title: The PI3K-delta Inhibitor TGR-1202 In Combination with Brentuximab

    Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and

    Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma

    Cell Line Xenografts

    -- Abstract Number: 4486

    -- Session: 625. Lymphoma: Pre-Clinical -- Chemotherapy and Biologic

    Agents: Poster III

    -- Date and Time: Monday, December 8, 2014: 6:00 PM-8:00 PM

    -- Location: West Building, Level 1

    -- Presenter: Silvia L. Locatelli, PhD

    Sentiment: Strong Buy

  • The US Navy Seal who fired the fatal gunshots at Osama bin Laden has revealed his identity.

    Commando Rob O’Neill was a key figure in Operation Neptune Spear, the daring night-time mission which saw the al-Qaeda chief shot and killed on May 2, 2011.

    O’Neill, 38, was the man who shot Bin Laden three times in the forehead during the SEAL raid on Abbottobad which also saw four others killed and no casualties among U.S. forces.

    His identity was revealed an a MailOnline interview with Rob’s father, Tom O’Neill - who insists he isn't scared of any retribution from his son's outing as the man who killed bin Laden.

    Tom O’Neill told MailOnline: ‘People are asking if we are worried that ISIS will come and get us because Rob is going public.

    I say I'll paint a big target on my front door and say come and get us.'

    Rob O'Neill is reportedly one of the most distinguished members of the Navy SEALs and was personally congratulated after killing bin Laden, according to his father.

    The raid in 2011 saw a team of Navy SEALs in Blackhawk helicopters swooping on Bin Laden's hideout in Abbottabad, Pakistan.

    The operation was ordered by President Barack Obama after the CIA traced Bin Laden's courier to the high-walled compound.
    NO FEAR

    Sentiment: Hold

  • Reply to

    TGR-1202 and Ublituximab Show Promise in CLL

    by golderw3 Nov 5, 2014 9:50 PM
    pharmatheway pharmatheway Nov 5, 2014 10:55 PM Flag

    Nice find!

    Sentiment: Strong Buy

  • Reply to

    Refutations of the Bearish Thesis

    by guessiamback Nov 3, 2014 2:47 AM
    pharmatheway pharmatheway Nov 3, 2014 4:40 PM Flag

    From 2013 .METHODS:
    From May 2013
    The murine lymphoma B-cell line A20.IIA-GFP-hCD20 (H-2(d)) was injected into the right cerebral striatum or the vitreous of immunocompetent adult BALB/c mice (H-2(d)). Four to 7 days later, ublituximab was injected intracerebrally or intravitreously into the tumor site. Rituximab was the reference compound. Survival was monitored for injected mice; histopathological and flow cytometric analyses were performed to study tumor growth and T-cell infiltration.
    RESULTS:

    Single doses of ublituximab, injected intracerebrally or intravitreously, had a marked antitumor effect, more pronounced than that obtained with the same dose of rituximab in these conditions. The reduction in tumor cells was correlated with an increased proportion of CD8(+) T cells. This efficacy was observed only against lymphoma B cells expressing hCD20.
    CONCLUSIONS:

    These in vivo results confirm the potential of the glycoengineered anti-hCD20 mAb ublituximab as an innovative therapeutic approach to treat primary central nervous system lymphoma and other B-cell lymphomas.As you could see rituximab doesn't even come close.

    Sentiment: Strong Buy

SNTA
3.18+0.09(+2.91%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST